Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre for Advanced Studies, Panjab University, Chandigarh, India.
Life Sci. 2011 Apr 25;88(17-18):784-91. doi: 10.1016/j.lfs.2011.02.020. Epub 2011 Feb 26.
The aim of this study was to investigate the protective effects of cyclo-oxygenase inhibitors against quinolinic acid (QA) induced Huntington's disease-like alterations in rats.
Quinolinic acid (300 nmol) was administered intrastriatally into the striatum to induce Huntington's disease-like alteration. Cyclo-oxygenase inhibitors celecoxib (15 and 30 mg/kg) and meloxicam (10 and 20mg/kg) were given for 21 days. In behavioral assessment locomotor, rotarod, and balance beam walk performances were assessed. Oxidative stress, mitochondrial dysfunction, proinflammatory cytokines and caspase-3 were assessed on day 21 after behavioral assessments.
Intrastriatal quinolinic acid (300 nmol) administration significantly altered the body weight, motor coordination, and induced oxidative damage (as indicated by the increase in lipid peroxidation and nitrite concentration) in the striatum as compared to sham group. Besides quinolinic acid (300 nmol) significantly depleted the mitochondrial enzyme complex levels and increased TNF-α, IL-6 and caspase-3 (marker of apoptotic cell death) levels in the striatum. Chronic treatment with celecoxib (15 and 30 mg/kg) significantly attenuated the quinolinic acid-induced behavioral and biochemical alterations, while meloxicam was able to reverse behavioral alterations at higher dose (20 mg/kg) as compared to the quinolinic acid treated group. Chronic treatment with the selective COX-2 inhibitors significantly restored the mitochondrial enzyme complex activities as well as attenuated TNF-α, IL-6 and caspase-3 levels as compared to the quinolinic acid treated group.
Results of the present study demonstrate the protective effect of cyclo-oxygenase inhibitors in the experimental models of Huntington's disease; and further provide evidence toward the involvement of neuroinflammatory cascade in the pathogenesis of Huntington's disease.
本研究旨在探讨环氧化酶抑制剂对喹啉酸(QA)诱导的大鼠似亨廷顿病改变的保护作用。
将喹啉酸(300nmol)注入纹状体以诱导似亨廷顿病改变。给予环氧化酶抑制剂塞来昔布(15 和 30mg/kg)和美洛昔康(10 和 20mg/kg)21 天。在行为评估中,评估了运动、旋转棒和平衡梁行走表现。在行为评估后第 21 天评估氧化应激、线粒体功能障碍、促炎细胞因子和 caspase-3。
与假手术组相比,纹状体内注射喹啉酸(300nmol)显著改变了体重、运动协调,并诱导了氧化损伤(如脂质过氧化和亚硝酸盐浓度增加所表明的)。此外,喹啉酸(300nmol)显著降低了线粒体酶复合物水平,并增加了纹状体中的 TNF-α、IL-6 和 caspase-3(凋亡细胞死亡的标志物)水平。与喹啉酸处理组相比,塞来昔布(15 和 30mg/kg)的慢性治疗显著减弱了喹啉酸诱导的行为和生化改变,而美洛昔康在较高剂量(20mg/kg)能够逆转行为改变。与喹啉酸处理组相比,选择性 COX-2 抑制剂的慢性治疗显著恢复了线粒体酶复合物活性,并减弱了 TNF-α、IL-6 和 caspase-3 水平。
本研究结果表明环氧化酶抑制剂在亨廷顿病的实验模型中具有保护作用;并进一步提供了证据表明神经炎症级联反应参与了亨廷顿病的发病机制。